NanoViricides, Inc
NanoViricides, Inc. is a global leader in the development of nanomedicine drugs against viruses, utilizing its unique nanoviricide platform technology to create first-in-class antiviral drugs. The company possesses its own state-of-the-art facilities for design, synthesis, analysis, and production of nanomedicines, enabling rapid development and potential early revenues from approved drugs. Its pipeline includes broad-spectrum nanoviricides targeting various viruses such as RSV, COVID-19, Flu, Smallpox, Herpes, Dengue, Rabies, Ebola, Marburg, HIV, and Hepatitis C. The technology mimics host cell receptors to fool viruses, leading to their neutralization and destruction, with a focus on safety and broad-spectrum efficacy.
Industries
Nr. of Employees
small (1-50)
NanoViricides, Inc
Products
Topical antiviral formulation for varicella‑zoster (shingles)
Route‑specific dermal cream designed to deliver high local concentrations of antiviral nanomicelles to treat shingles rash.
Broad‑spectrum respiratory antiviral candidate
Nanomicelle therapeutic intended for treatment of respiratory viruses (examples cited include RSV, coronaviruses, and influenza) designed for systemic or respiratory administration.
Antiviral candidates for neglected and hemorrhagic viruses
Nanomicelle-based therapeutics being developed against viruses such as Dengue, Rabies, Ebola/Marburg and other hemorrhagic viruses with a broad‑spectrum design approach.
Topical antiviral formulation for varicella‑zoster (shingles)
Route‑specific dermal cream designed to deliver high local concentrations of antiviral nanomicelles to treat shingles rash.
Broad‑spectrum respiratory antiviral candidate
Nanomicelle therapeutic intended for treatment of respiratory viruses (examples cited include RSV, coronaviruses, and influenza) designed for systemic or respiratory administration.
Antiviral candidates for neglected and hemorrhagic viruses
Nanomicelle-based therapeutics being developed against viruses such as Dengue, Rabies, Ebola/Marburg and other hemorrhagic viruses with a broad‑spectrum design approach.
Services
cGMP-capable pilot manufacturing for clinical supplies
Multi‑kilogram pilot production of drug substance and drug product suitable for supplying human clinical trials and initial commercial volumes.
Analytical characterization and QC in support of clinical development
Analytical method development, bioanalytical testing and quality control for nanomedicine drug substance and drug product.
Preclinical study coordination with external CROs and labs
Management and oversight of efficacy, biodistribution, and GLP safety/toxicology studies performed by external collaborators.
Formulation development for route-specific delivery
Development of topical, ocular, intravitreal and systemic formulations tailored to intended route of administration.
cGMP-capable pilot manufacturing for clinical supplies
Multi‑kilogram pilot production of drug substance and drug product suitable for supplying human clinical trials and initial commercial volumes.
Analytical characterization and QC in support of clinical development
Analytical method development, bioanalytical testing and quality control for nanomedicine drug substance and drug product.
Preclinical study coordination with external CROs and labs
Management and oversight of efficacy, biodistribution, and GLP safety/toxicology studies performed by external collaborators.
Formulation development for route-specific delivery
Development of topical, ocular, intravitreal and systemic formulations tailored to intended route of administration.
Expertise Areas
- Antiviral drug discovery
- Nanomedicine and polymeric micelle therapeutics
- Formulation development for topical and ocular routes
- Preclinical efficacy and GLP safety/toxicology studies
Key Technologies
- Nanomicelle-based targeted therapeutics
- Biomimetic ligand design for virus binding
- API encapsulation and controlled release
- Polymeric micelle synthesis and conjugation